

Johannes Walter

# LONGEVITY BY DESIGN

## AI, DATA AND HEALTHY AGEING

27.02.26

NEXA Center for Internet & Society - Polytechnico di Torino

# Longevity, Healthspan, and Healthy Ageing

...are three terms that are often confused.

## Longevity usually refers to lifespan...

the survival and mortality life expectancy at the population level.

How long do we live?

## The World Health Organization concept Of Healthy Ageing...

shifts the goal from living longer to functional ability, intrinsic capacity, participation & independence.

How well do we function as we age?

## The Healthspan is a widely used research shorthand...

for the years lived in good health. And is often explained as disease- and disability-free years, or through frailty and multimorbidity indicators

How many years are lived in good health?

**“Longevity by Design” means using continuous data and AI to protect function earlier while keeping responsibility and final clinical decisions with humans.**

# HEALTHY AGEING IS NOT “LIVING LONGER”

The World Health Organization defines...

*Healthy ageing is the process of developing and maintaining the functional ability that enables wellbeing in older age.*

## **Our Intrinsic capacity**

like Physical and  
mental capacities

## **Our Environment**

Supportive housing,  
services, communities

## **Our Functional ability**

What people  
can be and do

# So why now?

...because health system pressure is rising at the same time as technology readiness.

## On the systemic side...

- Chronic multimorbidity is rising and many disease processes have long trajectories
- Resource constraints and prioritisation becomes central
- Episodic care struggles to learn due to a lack of feedback loops.

## On the technology side...

- We now have broader measurement (standard labs, wearables, imaging and genetics)
- AI can help structure heterogeneous signals and translate signals into decisions
- But the Impact depends on integration into workflows and on governance.

# Systems biology

...focuses on interactions, feedback loops and emergent behaviours.

## You can't measure health using just one metric...

- Health is a emergent behaviour of coupled processes like metabolism, hormones, inflammation and behaviour
- But Chronic disease is dynamic
- Often we see compensation for a long time, then gradual drift and finally symptoms become visible
- Prevention requires monitoring systems, not only isolated markers

## Operationally that means...

- **Measuring functions**, like cardiorespiratory fitness, strength, mobility, cognition
- **Measuring stability**: metabolic control, inflammation, sleep and recovery capacity
- **Trajectories**: trends over time (not snapshots)
- **Multidimensional**: no single metric describes ageing end-to-end

**AI can integrate multiple weak signals into an interpretable picture**

# Healthcare is being forced

...to redesign its operating model.

## Today we have episodic models...

- Care starts when symptoms appear
- We use fragmented data across providers
- We have reactive decisions under time pressure
- Prevention is optional or underfunded

**The consequence is that learning is hard because outcomes and upstream signals are not routinely connected.**

Design challenge

## A Continuous model flips this logic...

- Care starts with risk signals, not only with symptoms.
- Data flows are interoperable across electronic health record and devices.
- Decision support is embedded in the workflow
- Prevention becomes continuous and personalized
- The system becomes a learning system: evaluate, improve and iterate.

**ARTIFICIAL INTELLIGENCE SUPPORTS HEALTHY AGEING  
BUT ONLY WHEN IT IS DESIGNED AS PART OF  
A SOCIO-TECNICAL  
SYSTEM.**

# There are three high-value roles for AI in healthy ageing

...with responsibility and final decisions staying with humans.

## Early risk detection

AI can identify frailty risk or detect silent disease earlier than traditional episodic care with multiple sources over time

**Decision support and  
Human-in-the-loop**

## Better prevention

AI can help personalize interventions, identify who could benefit and support adherence through coaching.

**Decision support and  
Human-in-the-loop**

## Clinical decision support

AI can support triage and prioritization, act as a second reader for imaging and reduce medication safety

**Decision support and  
Human-in-the-loop**

# Healthy ageing needs multi-source data

...Electronic Health Record alone is rarely enough.

## When we add sources...

**Wearables contribute**  
activity, sleep,  
Heart Rate Variability  
(HRV)

**Labs contribute**  
trends and  
reference ranges  
interpretation.

**Imaging can**  
reveal early  
patterns

**Social context**  
shapes exposure care  
access, and feasibility  
of interventions.



**EHR / clinical  
workflow**

Every additional source  
increases the need for consent  
management, data quality  
controls, provenance and  
accountability

# The data pyramid

...is a pragmatic approach that connects scientific ambition with real-world scalability.

## At the top we have...

deep phenotyping like proteomics, metabolomics, advanced imaging.  
These are powerful for discovering subgroups, but expensive.

## In the middle we have...

core measurements like standard labs, polygenetic risk scores, continuous glucose monitoring,  
in some settings also microbiome and genetics profiles

## At the bottom we have...

scalable, broad signals: wearables, smartphone proxies, questionnaires.  
They are imperfect, but can reach many people, continuously at low costs

## The design principle is...

- Use deep data to learn which mechanisms matter and which subgroups exist
- Then translate the insights into scalable signals to screen and trigger targeted follow-up.

# Multiomics is attractive

...because it measures multiple orthogonal biological layers.

## **The value proposition is...**

higher sensitivity to pathway-level dysregulation and to stratify responders versus non-responder.

**This matters because in prevention and treatment averages often hide meaningful heterogeneity.**

## **Multiomics only helps if methods are rigorous...**

We have to control multiple testing , define prospective endpoints and interpret results in context like age, medications or lifestyle

**If multiomic signals are used to guide interventions we need replication and intervention studies to support causality**

# Genetics & polygenic risk scores (PRS)

...provide a risk lens but not determinism

## Practically polygenic risk scores can help...

- Prioritize monitoring and prevention
- Identify who is likely to respond to which interventions

## The key limitations are...

- Transferability across populations can be limited
- Explained variance is trait-dependent but not a diagnosis
- Always interpret with phenotype, environment and trajectories

# Wearables can turn “annual snapshots” into “daily signals”

That is a major shift for prevention, but only if we define the action chain.

## A practical “signal to action” ladder could be...

- 1 A drop in steps for 7 days** → trigger check-in message or a call
- 2 Sleep disruption and HRV change** → might trigger a medication, stressors review
- 3 An Arrhythmia alert** → needs confirmation and clinical triage
- 4 Repeated falls or near-falls** → point to home safety interventions and physiotherapy



# Remote monitoring in real-world settings

... the research project ALFREDO as a practical example of what is feasible.

## Research Project: Alfredo

- The Goal was continuous, preventive monitoring in real-world ageing care
- Smart watches and home devices captured relevant physiological signals like sleep, Heart Rate, ECG, steps or weight.
- ALFREDO combined monitoring with online one-to-one coaching and online group coaching sessions to increase participation and medical verification (human-in-the-loop)
- The implementation involved partners including health insurer or the the alzheimer society

## The Value comes from the closed loop:

Continuous data produces insights, coaching and medical consultation workflows turn insights into action and outcomes can then be evaluated.

For example, we had prevented a stroke in a participant and identified sleep apnoea.

**Outcomes: earlier risk detection and targeted follow-up instead of blanket screening / impact comes from the closed loop**

# Decision support works when it saves attention

...when it reduces cognitive load and administrative work.



Imaging triage

## Design constraints are:

1. Decision support must be embedded In-the-moment of work: inside EHR, not separate systems
2. Must provide calibrated confidence
3. Explainability should match the task
4. Clear escalation paths and documentation must be defined

## Reality check

Decision support fails when it demands attention by adding dashboards or unmanageable alerts.

The most common AI deployments are often narrow: imaging triage, measurement tools and specific screening tasks.

# Feasibility

...depends on evidence and workflow fit

Area	Now	Next Steps are	Future Steps are
<b>Detection</b>	Imaging triage, measurement tools	Multimodal risk prediction that combines several sources	General-purpose clinical copilots, but only if they are verified, governed and integrated
<b>Prevention</b>	Rule-based and simple personalization	Adaptive programs that are evaluated in real settings	Future Vision could be the closed-loop prevention at scale (continuous signals feeding into interventions)
<b>Operations</b>	Administrative automation is already feasible (scheduling, documentation support)	Optimizing care coordination	Future Vision could be System-level resource allocation, but fair, transparent and accountable

# Without Interoperability

...every integration becomes a one-off project. That means high costs and poor scalability.

A pragmatic interoperability stack has several layers:

**Clinical Terminologies Standards**

such as SNOMED CT define shared meaning

**Common Data models**

such as OMOP supports research and analytics across institutions

**HL7 FHIR**

supports exchange through APIs for clinical data

**Workflow**

Integration connects data to action inside EHR apps and clinical pathways

If you want to standardize something first:

Focus on...

- patient identity and consent metadata,
- core clinical concepts like (problems, medication, labs),
- event timestamp, provenance and
- clear outcome definitions for evaluation.

**Interoperability means Scalability**

# Trust and Health data Protection

...are infrastructure requirements, not optional add-ons.

## Under GDPR...

health, genetic and biometric data are special category data.  
Processing is prohibited by default, with defined exceptions under Art.9

### That means every deployment needs a lawful basis under Art. 9:

- Purpose limitation, data minimization, strong security and access controls.
- Patients need transparency about what data is used, why and with which safeguards

## On the AI regulation side, the EU AI Act...

introduces Risk-based obligations, especially for high risk and regulated systems in health care.

### It requires....

- documentation, transparency, human oversight,
- governance structures and market surveillance.

# Implementation

... is a socio-technical problem. AI projects fail because the surrounding system is not designed.

## On the Data side...

we see missingness,  
bias, label leakage or  
poor provenance.

### Must fixed by design...

through careful  
cohort definition,  
data contracts and  
audit trails.

## On the Model side...

generalization gaps,  
drift and miscalibrated  
uncertainty are common.

### Must fixed by design...

through external  
validation, monitoring  
and conservative  
deployment strategies.

## On the Workflow side...

alert fatigue, no capacity  
to act and misaligned  
incentives can reduce the  
value.

### Must fixed by design...

through embed AI in  
pathways that already  
exist, reduce work and  
ensure there is  
operational capacity.

## On the Governance side...


unclear accountability  
privacy, legal gaps and  
procurement friction can  
stop a project.

### Must fixed by design...

through clear roles,  
incident handling and  
continuous oversight.

# Regulated environments

... need controlled experimentation.



## Regulatory Sandboxes could enable:

### For Regulators...

- Sandboxes support learning-by-testing
- They inform long-term policy through experimentation
- Improve communication with market participants

### For Firms...

- Can reduce time to market by streamlining authorization
- Reduce uncertainty about new technologies or business models
- Provide feedback on requirements and risks

### For Consumers...

- Sandboxes can accelerate access to new and potentially safer products and services

Source: Adapted from OECD, REGULATORY SANDBOXES IN ARTIFICIAL INTELLIGENCE (2023)

# Takeaways

- 1 Start with outcomes** Define the healthspan outcomes you care about and the decision you intend to change.
- 2 Design the data supply chain** Be sure about purpose, ownership, interoperability, retention. Data without governance becomes a liability.
- 3 Make evaluation non-negotiable** Use standards and measure utility, safety and equity. If you cannot evaluate, you cannot scale responsibly.
- 4 Embed in workflows** The design goal is to remove work, don't add dashboards. Adoptions follows convenience.
- 5 Govern with clarity** Define Roles, accountability, monitoring, incident handling. Governance is how you maintain trust over time.

# THANK YOU

Contact:

Johannes Walter

IU University of Applied Sciences

 [johannes.walter@iu.org](mailto:johannes.walter@iu.org)

 +491723759574

# Questions, Suggestions, Wishes?

## SELECTED REFERENCES

World Health Organization. (2015). World report on ageing and health. WHO.

European Union. (2024). Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). Official Journal of the European Union.

European Union. (2016). Regulation (EU) 2016/679 (General Data Protection Regulation). Official Journal of the European Union.

European Commission. (2025, February 6). Guidelines on the definition of an AI system established by Regulation (EU) 2024/1689 (AI Act).

Organisation for Economic Co-operation and Development. (2023). Regulatory sandboxes in artificial intelligence (OECD Digital Economy Papers No. 356).

Kordowitzki, P., & Ying, K. (2026). The pursuit of understanding human longevity. *npj Aging*, 12, 25 (Published 05 Feb 2026).

Edouard, P., Campo, D., & Escourrou, P. (2021). Validation of the Withings Sleep Analyzer, an under-the-mattress device for the detection of moderate-severe sleep apnea syndrome. *Journal of Clinical Sleep Medicine*

Badertscher, P., et al. (2022). Clinical validation of a novel smartwatch for automated detection of atrial fibrillation. *Heart Rhythm* 02, 3(3)

Mannhart, D., et al. (2023). Clinical validation of 5 direct-to-consumer wearable devices for atrial fibrillation screening. *JACC: Clinical Electrophysiology*, 9(2)

ALFREDO project. (2022). Preventive monitoring and AI-supported care pathways using wearables (project materials and pilot reports).

## ACRONYMS GLOSSARY AND MEANING

- **AI in Healthcare** — *Artificial Intelligence*: Methods that learn patterns from data to support predictions, classification, and decision support.
- **ML** — *Machine Learning*: Subfield of AI focused on models that improve performance by learning from examples rather than hard-coded rules.
- **LLM** — *Large Language Model*: AI model trained on large text corpora to generate and interpret language; useful for summarisation, drafting, and “knowledge navigation,” but needs governance to avoid errors.
- **CDS** — *Clinical Decision Support System*: Tools that assist clinicians with recommendations/alerts; final responsibility remains with human decision-makers.
- **EHR/EMR** — *Electronic Health Record / Electronic Medical Record*: Digital patient records; core data source but often fragmented across providers/systems.
- **GDPR** — *General Data Protection Regulation (EU)*: Legal framework for personal data processing; defines lawful basis, rights, safeguards, and compliance duties.
- **AI Act** — *EU Artificial Intelligence Act*: EU regulation classifying AI systems by risk level and imposing obligations (e.g., documentation, transparency, oversight) for high-risk use cases.
- **Interoperability**: Ability of systems to exchange and correctly use data; essential for “data-based care” beyond silos.

### Data standards / terminologies

- **HL7** — *Health Level Seven*: Organisation behind major healthcare messaging standards; foundational for exchanging clinical data.
- **FHIR** — *Fast Healthcare Interoperability Resources*: Modern HL7 standard using “resources” + APIs for health data exchange; enables scalable integration across systems.
- **OMOP** — *Observational Medical Outcomes Partnership (Common Data Model)*: Standard data model used to harmonise observational health data for analysis across institutions.
- **SNOMED CT** — *Systematized Nomenclature of Medicine—Clinical Terms*: Clinical terminology for consistent coding of diagnoses/clinical concepts.

### Wearables / clinical signals

- **ECG (or EKG)** — *Electrocardiogram*: Measures the heart’s electrical activity; helps detect arrhythmias (e.g., atrial fibrillation).
  - **HR** — *Heart Rate*: Basic cardiovascular signal; useful for fitness and acute stress/illness signals.
  - **HRV** — *Heart Rate Variability*: Variation in time between heartbeats; proxy for autonomic balance, recovery, stress, and illness signals.
  - **BP** — *Blood Pressure*: Key cardiovascular risk factor; continuous or frequent monitoring can enable earlier intervention.
  - **SpO<sub>2</sub>** — *Peripheral Oxygen Saturation*: Proxy for blood oxygenation; useful for respiratory issues and sleep-related breathing disorders.
  - **AF** — *Atrial Fibrillation*: Common arrhythmia; detection via wearables can trigger confirmatory diagnostics and stroke-risk management.
  - **OSA** — *Obstructive Sleep Apnea*: Sleep breathing disorder; wearables/home sensors can flag risk and trigger formal diagnostic follow-up.
- **Trials / evaluation**
- **RCT** — *Randomised Controlled Trial*: Gold-standard design for causal evidence; often slow/expensive but critical for clinical claims.
  - **ROC** — *Receiver Operating Characteristic (curve)*: Plots sensitivity vs. false-positive rate to evaluate classifiers.
  - **PPV / NPV** — *Positive/Negative Predictive Value*: Probability that alerts are true (PPV) or negatives are truly negative (NPV); depends on prevalence and matters for real-world deployment.
  - **Sensitivity / Specificity**: Sensitivity = true positive rate; specificity = true negative rate; both shape clinical usefulness and workload.

### Genetics / biomarkers (if you mention them)

- **PRS** — *Polygenic Risk Score*: Aggregate genetic risk estimate from many variants; helps stratify risk but varies by ancestry and dataset.
- **LDL / HDL** — *Low-/High-Density Lipoprotein Cholesterol*: Lipid markers used in cardiovascular risk assessment.
- **CGM** — *Continuous Glucose Monitor*: Tracks glucose continuously; supports “N-of-1” lifestyle experiments and personalised feedback loops.